Bridget C. Scullion, PHARMD, BCOP
Oncology Pharmacist · Boston, MA
Bridget C. Scullion, PHARMD, BCOP is an oncology pharmacist with a practice address in Boston, Massachusetts, and NPI 1487122719, issued on Nov 5, 2018. Check the license (Massachusetts PH25263, as entered in NPPES) with the Massachusetts board that licenses this profession; the Medicare figures below come from public CMS files.
- Name
- Bridget C. Scullion
- Credential
- PHARMD, BCOP
- Primary taxonomy
- Oncology Pharmacist 1835X0200X
- License number
- PH25263 MA
Self-reported in NPPES; status is on the state search - Practice location
- 450 Brookline Ave Dept OF, Boston, MA 02215
- Phone
- (617) 632-4261
- Enumerated
- Nov 5, 2018
- Record last updated
- Nov 5, 2018 (not updated in 8 years: call before relying on the address or phone)
- Entity
- Type 1 · individual
Also registered at 450 Brookline Ave Dept OF
A shared address usually means a shared clinic or building; it does not show who employs whom.
- Hyesun Park, MDDiagnostic Radiology Physician1215450820
Verify Bridget C. Scullion in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersWhich Massachusetts board licenses this profession
Search for license PH25263Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
86% fewer Medicare Part D claims than the average oncology pharmacist in 2024
24 Medicare Part D claims, against an average of 177 among the 69 providers of this specialty who prescribed in Part D. 20 claims were for opioids.
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
Oncology Pharmacist providers in Massachusetts
There are 51 oncology pharmacist records in Massachusetts.
Other oncology pharmacist records in Massachusetts
- Sheila Adjei Poku, RPH, BCOPFoxborough, MA1578414397
- Shaziya Barkat, PHARMDStoughton, MA1871090076
- Jayde Bednarik, PHARMDWorcester, MA1740589514
- James Bennett, PHARMDBoston, MA1447648779
- Carmela Berlin, RPHDanvers, MA1144584301
- Edward Bisaga, RPHWest Roxbury, MA1568681591
- Lauren BrothersWorcester, MA1992309223
- Robert Cersosimo, PHARM.D.Boston, MA1558445189
- Tsz-Yi ChenBoston, MA1326663964
- Rose Cheng, PHARMDMalden, MA1912429382
Common questions
What is Bridget C. Scullion, PHARMD, BCOP's NPI number?
Bridget C. Scullion, PHARMD, BCOP's National Provider Identifier (NPI) is 1487122719, issued on Nov 5, 2018. An NPI identifies a provider in billing; it is not a license.
Where is Bridget C. Scullion, PHARMD, BCOP located?
The NPPES record lists a practice address at 450 Brookline Ave Dept OF, Boston, MA, 02215. Phone: (617) 632-4261. Providers update this record themselves, so call before visiting.
How can I verify Bridget C. Scullion, PHARMD, BCOP's license?
NPPES lists Massachusetts license number PH25263, as entered by the provider. Search the Massachusetts board that licenses this profession; the NPPES record confirms identity only.
How much does Bridget C. Scullion, PHARMD, BCOP prescribe under Medicare Part D?
In 2024, Bridget C. Scullion, PHARMD, BCOP had 24 Medicare Part D claims; the average among oncology pharmacist prescribers was 177. Part D covers Medicare prescriptions only.
Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.